Novo Nordisk A/S
- Industry
- Pharmaceuticals
- Exchange
- US
- Country
- USA
- IPO date
- Jan 4, 1982
- Employees
- 67,900
- Website
- www.novonordisk.com
Composite valuation range · conservative $28–$34 / fair $40–$50 / optimistic $56–$67. At $49.67, Within the fair intrinsic-value range.
At publication $44.74 (May 17, 2026)
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
History
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark, with an IPO date of 1982-01-04. The company researches, manufactures, and distributes pharmaceutical products through two segments, Obesity and Diabetes Care, and Rare Disease. Its products include GLP-1 medicines such as Ozempic and Wegovy, insulin, the NovoPen 6 and NovoPen Echo Plus smart insulin pens, the Dose Check application, and growth hormone pens. By 2025 it employed about 67,900 people, and Wegovy had launched in more than 55 countries.
Industry position
Novo Nordisk works in the Healthcare sector under Drug Manufacturers - General, operating across Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. In its Q1 2026 materials it described itself as the global volume-share leader in weekly-injectable GLP-1 at about 55%, and as the world's largest manufacturer of insulin and GLP-1. Revenue grew from DKK 122.0 billion in 2019 to DKK 309.1 billion in 2025. Novo Holdings, backed by the Novo Nordisk Foundation, holds 28.05% of capital and 77.28% of voting rights.